You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 複星醫藥升超7%,合作方開發的新冠疫苗獲美國政府採購
uSMART友信智投 07-23 11:48

uSMART友信智投7月23日消息,週四港A兩市,複星醫藥AH股齊齊大升,截至10:37分,複星醫藥H股升6.95%,市中最高升幅7.8%,A股升7.35%。

此前合作方BioNTech與輝瑞聯合開發的新冠疫苗獲美國政府20億美元採購協定。 

據《華爾街日報》報導,輝瑞公司和BioNTech SE週三表示,已與美國衛生與公共服務部及國防部簽署了一項19.5億美元的協議,將提供數億劑2019冠狀病毒病(Covid-19)疫苗,美國人將免費接種疫苗。

根據該協定,美國政府將獲得1億劑BNT162疫苗,並可額外獲得多達5億劑疫苗。BNT162是輝瑞和BioNTech聯合開發的Covid-19候選疫苗,將由輝瑞生產。BNT162專案基於BioNTech的專有mRNA技術,並得到輝瑞全球疫苗研發和生產能力的支持。BNT162候選疫苗正在進行臨床研究,目前還沒有獲得批准在世界任何地方使用。

7月13日,複星醫藥公告稱,控股子公司獲BioNTech授權的新冠疫苗獲得國家藥品監督管理局批准進行人體臨床試驗。

 

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account